Anticuerpos Monoclonales/uso terapéutico; Azatioprina/uso terapéutico; Enfermedad de Crohn/diagnóstico; Enfermedad de Crohn/tratamiento farmacológico; Endoscopía Gastrointestinal/métodos; Fármacos Gastrointestinales/uso terapéutico; Índices de Gravedad del Trauma; Adulto; Anticuerpos Monoclonales/farmacología; Azatioprina/farmacología; Estudios de Cohortes; Enfermedad de Crohn/patología; Progresión de la Enfermedad; Quimioterapia Combinada; Femenino; Fármacos Gastrointestinales/farmacología; Humanos; Infliximab; Mucosa Intestinal/efectos de los fármacos; Masculino; Reproducibilidad de los Resultados; Estudios Retrospectivos; Sensibilidad y Especificidad; Resultado del Tratamiento

AUC; C-reactive protein; CD; CDAI; CDEIS; CFREM; CI; CRP; Crohn's Disease Activity Index; Crohn's Disease Endoscopy Index of Severity; Crohn's disease; IBD; MH; Mucosal Healing; NLR; PLR; Prognosis; REM; RESΔ100; RESΔ70; ROC; Response to Therapy; SES-CD; SMH; SONIC; Simple Endoscopic Score for Crohn's disease; Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease; area under the curve; clinical remission; clinical response with at least a 100-point reduction in Crohn's Disease Activity Index score; clinical response with at least a 70-point reduction in Crohn's Disease Activity Index score; confidence interval; corticosteroid-free clinical remission; mucosal healing; negative likelihood ratio; positive likelihood ratio; receiver operating characteristic; segmental mucosal healing